Effects of Intra-uterine Slow-Release Insemination on Pregnancy Rate in Women Designated for Artificial Insemination
NCT ID: NCT00745563
Last Updated: 2011-06-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
100 participants
INTERVENTIONAL
2008-10-31
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Three common methods of artificial insemination:
1. Placement of a diaphragm that contains raw spermatozoa or isolated improved spermatozoa in an appropriate liquid solution (Cup insemination, CI) upon the cervix.
2. Spermatozoa injection (after improvement) through the vagina to the cervix (Intra-Cervical Insemination, ICI).
3. Spermatozoa injection (after improvement) directly into the uterus (IUI-Intra-Uterine Insemination).
The EVIE - Slow Release Insemination method:
The slow release insemination is utilizing a Grasby type MS16 pump for 3 hours. The release rate for motile spermatozoa is 50X103 per minute.
Advantages:
* Very close approximation of the natural procedure in which the spermatozoa arrive to the fertilization site over a long period.
* An extended "window of opportunities" for meeting between the ovum and spermatozoa will be longer.
* There is no loss of spermatozoa due to leaking as sometimes happens with single-time injection practiced in the IUI method.
Primary Endpoint:
Accumulation of 50 cycles of SRI- slow release insemination (study group) in addition to 50 cycles of regular IUI (control group). Two weeks after insemination Beta hCG test
Secondary Endpoints:
Four weeks after insemination - US Viability scan
Procedure:
Subjects will be women with fertility difficulties who are designated for IUI treatment. 100 insemination cycles will be conducted. (50 regular IUI and 50 EVIE-SRI). Subjects that were treated with the IUI method and who does not become pregnant will then be treated with the EVIE-Slow Release method and vice versa.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observation of the Response to Ovulation Triggering on the Day of Intrauterine Insemination and Correlation Between Progesterone Level and Pregnancy Rate (OVUL-IIU)
NCT07038616
Intrauterine Injection of Human Chorionic Gonadotrophin and Pregnancy Rate in ICSI
NCT03445910
Infertility Therapy for Women Age Thirty-eight and Older
NCT00246506
Optimal Timing of Intrauterine Insemination (IUI) When Utilizing Superovulation Combined With GnRH Antagonists
NCT00675142
Improving in Vitro Fertilization in Women With Poor Ovarian Response
NCT04024722
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Fertiligent
Fertility treatment by using the EVIE - Slow Release Insemination method
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fertiligent
Fertility treatment by using the EVIE - Slow Release Insemination method
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age of candidates: 20-40 years.
* Normal uterus x-ray.
* Women suffering from infertility on a background of non-ovulation.
* Infertility on a background of male problems (over 10 million of motile sperm cells per sample).
* Infertility on background of unexplained problem
* Same sex patients / single patient
* Written informed consent
Exclusion Criteria
* Female infertility on mechanical background (different blockages, irregular uterus).
* Infertility on male background of medium to very low level of spermatozoa - less than 10 million motile sperm cells per sample.
* Men and women who are opposed to the random spermatozoa insemination method.
* Participants who are not willing to sign the Consent Form.
20 Years
40 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fertiligent
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fertiligent
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Martha Dirnfeld, Prof.
Role: PRINCIPAL_INVESTIGATOR
Carmel medical Center, Haifa Israel
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Carmel Medical Center
Haifa, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BRIDGE1 20/7/2008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.